Theta Burst Stimulation for Motor Recovery

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05613686
Collaborator
(none)
60
1
3
24
2.5

Study Details

Study Description

Brief Summary

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. This study will compare efficacy of different doses iTBS in combination with inhibitory rTMS on motor recovery and cortical excitability in subacute stroke patients.

Condition or Disease Intervention/Treatment Phase
  • Device: repetitive transcranial magnetic stimulation
N/A

Detailed Description

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology.

High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect. Through modulating the excitability of bilateral hemispheres, rTMS could facilitate motor recovery in stroke patients.

This study will compare efficacy of different doses iTBS in combination with inhibitory rTMS on motor recovery and cortical excitability in subacute stroke patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparative Efficacy of Different Doses of Theta Burst Stimulation for Motor Recovery in Stroke Patients
Actual Study Start Date :
Oct 29, 2022
Anticipated Primary Completion Date :
Oct 29, 2024
Anticipated Study Completion Date :
Oct 29, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: contralateral 1Hz+ipsilateral iTBS 1

Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 1

Device: repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.

Experimental: contralateral 1Hz+ipsilateral iTBS 2

Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 2

Device: repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.

Active Comparator: contralateral 1Hz

Patients received contralateral 1 Hz and ipsilateral sham iTBS

Device: repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.

Outcome Measures

Primary Outcome Measures

  1. Fugl-Meyer Assessment [12 weeks post intervention]

    Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.

Secondary Outcome Measures

  1. Medical Research Council (MRC) Scale for Muscle Strength [1 week, 4 weeks, 12 weeks and 24 weeks post intervention]

    Medical Research Council (MRC) Scale for Muscle Strength, assessing muscle strength from Grade 5 (normal) to Grade 0 (no visible contraction).

  2. National Institutes of Health Stroke Scale [1 week, 4 weeks, 12 weeks and 24 weeks post intervention]

    National Institutes of Health Stroke Scale, The maximum possible score is 42, with the minimum score being a 0. Higher scores indicate a worse outcome.

  3. Barthel Index [1 week, 4 weeks, 12 weeks and 24 weeks post intervention]

    Barthel Index, score 100-0. Higher scores indicate a better outcome.

  4. Modified Rankin Scale [1 week, 4 weeks, 12 weeks and 24 weeks post intervention]

    Modified Rankin Scale, score from 0 to 6. Higher scores indicate a worse outcome.

  5. MEP [1 week, 4 weeks, 12 weeks and 24 weeks post intervention]

    motor evoked potential

  6. Fugl-Meyer Assessment [1 week post intervention]

    Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.

  7. Fugl-Meyer Assessment [4 weeks post intervention]

    Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.

  8. Fugl-Meyer Assessment [24 weeks post intervention]

    Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 1.Unilateral ischemic or hemorrhagic stroke

  • 2.Stroke within 3 months

  • 3.Medical Research Council Scale for Muscle Strength in upper limb ≤ 3

  • 4.No previous stroke, seizure, dementia, Parkinson's disease or other degenerative neurological diseases.

  • 5.Patient could sit over 15 minutes

  • 6.Age over 20

Exclusion Criteria:
  • 1.Previous stroke, traumatic brain injury, brain tumor

  • 2.With central nervous system disease (spinal cord injury, Parkinson's disease)

  • 3.Any contraindication to rTMS (seizure, alcoholism, metal implant, pacemaker)

  • 4.Patients unable to cooperate the treatment

  • 5.Pregnancy

  • 6.Depression

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Taiwan University Hospital Taipei Taiwan 100

Sponsors and Collaborators

  • National Taiwan University Hospital

Investigators

  • Principal Investigator: Meng Ting Lin, M.D., The Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT05613686
Other Study ID Numbers:
  • 202204105DINB
First Posted:
Nov 14, 2022
Last Update Posted:
Nov 14, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 14, 2022